Biomarkers of human papillomavirus (HPV)-driven head and neck cancer in Latin America and Europe study: Study design and HPV DNA/p16<sup>INK4a</sup> status.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34726297.
- Also identified by DOI 10.1002/hed.26912.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Human papillomavirus (HPV)-driven head/neck squamous cell carcinomas (HNSCC) prevalence varies globally. We evaluated HPV DNA and p16<sup>INK4a</sup> in formalin fixed paraffin embedded (FFPE) HNSCC from Argentina, Brazil, Colombia, and Peru. HPV was genotyped by PCR-hybridization. All HPV DNA positive and some HPV DNA negative cases underwent p16<sup>INK4a</sup> immunohistochemistry. HPV DNA was detected in 32.8%, 11.1%, and 17.8% of oropharyngeal (OPC), oral cavity (OCC) and laryngeal (LC) cancers, respectively. OPC HPV prevalence was higher in Colombia (94.7%), and Argentina (42.6%) compared to Brazil (10.6%) and Peru (0.0%). HPV-16 was the most detected. Other HPVs were found in LC. Higher rates of p16<sup>INK4a</sup> positivity were observed among HPV positive OPC/OCC cases compared to LC cases. Our results support a role for HPV-16 in a subset of HNSCC, corroborate the heterogeneity observed in samples from different countries, and contribute additional etiological and biomarkers information in tumors of significant impact worldwide.
Medical subject headings
- Alphapapillomavirus
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Papillomavirus Infections